Uncategorized

Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy

Published

on

The FDA plans to hold an advisory committee meeting to discuss Capricor Therapeutics’ application for deramiocel, which the agency rejected last July. The news surprised CEO Linda Marbán, who told BioSpace the FDA has not communicated any issues of concern with the company’s resubmitted application.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version